The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000993392p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
29/06/2026
Date registered
Help: Date registered
12/08/2026
Date last updated
Help: Date last updated
12/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Randomised Controlled Trial Comparing Laparoscopic-Guided and Ultrasound-Guided Transversus Abdominis Plane (TAP) Blocks for Robotic Gynaecological Surgery
Scientific title
A Randomised Controlled Trial Comparing Laparoscopic-Guided and Ultrasound-Guided Transversus Abdominis Plane (TAP) Blocks for Robotic Gynaecological Surgery
Additional trial identifiers [1] 317738 0
Nil
Universal Trial Number (UTN)
Trial acronym
RoGyLAPvTAP
Related trial records

Health condition
Health condition(s) studied:
Endometriosis 342631 0
Fibroid 342632 0
Dysmenorrhea 342633 0
Condition category
Condition code
Anaesthesiology 338777 338777 0 0
Pain management
Reproductive Health and Childbirth 338778 338778 0 0
Other reproductive health and childbirth disorders
Surgery 339133 339133 0 0
Other surgery

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants randomised to the laparoscopic-guided TAP block arm will receive a bilateral transversus abdominis plane (TAP) block performed by the operating gynaecological surgeon under direct laparoscopic visualisation during robotic surgery for a benign gynaecological indication. During the robotic procedure and prior to skin closure, a standardised lateral TAP block technique will be used. Under laparoscopic visualisation, a regional anaesthesia needle will be inserted percutaneously at the mid-axillary line between the costal margin and iliac crest. The needle tip will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles. Correct placement will be confirmed by laparoscopic visualisation of tissue-plane hydrodissection following injection of a small test volume. Following negative aspiration, 20 mL of ropivacaine 0.2% will be injected incrementally into the transversus abdominis plane on each side (40 mL total). The TAP block is expected to add approximately 5–10 minutes to the operative procedure. Intervention fidelity and adherence will be assessed through review of operative records, anaesthetic records, medication administration records and REDCap intraoperative case report forms, which will document completion of the allocated TAP block, timing relative to surgery, proceduralist, local anaesthetic agent, dose and volume administered, procedure duration, and any protocol deviations.
Intervention code [1] 334573 0
Treatment: Surgery
Intervention code [2] 334681 0
Treatment: Drugs
Description of the comparator or control
Participants randomised to the comparator arm will receive a bilateral ultrasound-guided lateral transversus abdominis plane (TAP) block performed by the attending anaesthetist at the completion of surgery and prior to skin closure. Consistent with standard practice and to ensure comparability between study groups, the same local anaesthetic regimen used in the intervention arm will be administered: ropivacaine 0.2%, 20 mL per side (40 mL total), injected into the transversus abdominis plane under ultrasound guidance. The ultrasound-guided TAP block is expected to add approximately 5–10 minutes to the procedure. Intervention fidelity and adherence will be assessed through review of operative records, anaesthetic records, medication administration records and REDCap intraoperative case report forms, which will document completion of the allocated TAP block, timing relative to surgery, proceduralist, local anaesthetic agent, dose and volume administered, procedure duration, and any protocol deviations.
Control group
Active

Outcomes
Primary outcome [1] 345973 0
Oral morphine equivalent (mg)
Timepoint [1] 345973 0
24 hour period from surgical closure
Secondary outcome [1] 463983 0
Pain score at rest
Timepoint [1] 463983 0
24hr postoperative period
Secondary outcome [2] 463984 0
Pain score with movement
Timepoint [2] 463984 0
24hr postoperative period
Secondary outcome [3] 463987 0
Nausea
Timepoint [3] 463987 0
24hr postoperative
Secondary outcome [4] 464628 0
Length of stay
Timepoint [4] 464628 0
At hospital discharge
Secondary outcome [5] 464629 0
Total operative time
Timepoint [5] 464629 0
At time of operation
Secondary outcome [6] 464630 0
Console time (time of active use of robotic system)
Timepoint [6] 464630 0
At time of operation
Secondary outcome [7] 464631 0
Intraoperative complication rate (e.g. local anaesthetic toxicity, hemorrhage, viscous injury)
Timepoint [7] 464631 0
Intra-operative
Secondary outcome [8] 464634 0
Occurrence of vomiting
Timepoint [8] 464634 0
24 hour postoperative
Secondary outcome [9] 464635 0
Antiemetic use
Timepoint [9] 464635 0
24 hour postoperative period

Eligibility
Key inclusion criteria
To be eligible to enter the study all patients must satisfy the following criteria:
1. Adult aged 18 years and over;
2. Undergoing gynaecological surgery for a non-cancer indication at Royal Prince Alfred Hospital (RPAH);
3. Clinically suitable for robotic procedures;
4. Cognitively able to give written informed consent for participation;
5. Elective procedure.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Patients will be excluded if they present the following exclusion criteria:
1. The patient lacks the ability to consent for themselves;
2. Patients unwilling to complete pre- and post-operative assessment;
3. Patient factors precluding robotic surgery.
4. Chronic opioid use (defined as daily use)
5. Allergy to local anaesthetics
6. Epidural or spinal anaesthesia planned

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be randomly assigned in a 1:1 ratio to receive either a laparoscopic guided TAP block or an ultrasound guided TAP block. Randomization will be performed using a computer generated sequence created by an independent researcher not involved in recruitment, clinical care, or outcome assessment. To maintain balance between groups throughout the enrolment period, randomization will use permuted blocks of four with no stratification factors.
Treating clinicians, research staff responsible for enrolment, and outcome assessors will remain blinded to the upcoming allocation. Allocation will be revealed only at the time of surgery to the clinician performing the TAP block.
Allocation concealment will be maintained until all participants have been randomized and data collection is complete. Patients, other clinicians and outcome assessors will remain blinded to which form of TAP block was provided post-operatively.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322280 0
Government body
Name [1] 322280 0
Syndey Local Health District
Country [1] 322280 0
Australia
Primary sponsor type
Individual
Name
Dr Harry Baxter, Gynaecology Fellow
Address
Country
Australia
Secondary sponsor category [1] 325193 0
Individual
Name [1] 325193 0
A/Prof MIchael Cooper, Consultant Gynaecologist
Address [1] 325193 0
Country [1] 325193 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320796 0
Sydney Local Health District Ethics Review Committee (RPAH Zone)
Ethics committee address [1] 320796 0
Ethics committee country [1] 320796 0
Australia
Date submitted for ethics approval [1] 320796 0
25/05/2026
Approval date [1] 320796 0
Ethics approval number [1] 320796 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151658 0
Dr Harry Baxter
Address 151658 0
Royal Prince Alfred Hospital, 50 MIssenden Rd, Camperdown NSW 2050
Country 151658 0
Australia
Phone 151658 0
+61 295156111
Fax 151658 0
Email 151658 0
Contact person for public queries
Name 151659 0
Harry Baxter
Address 151659 0
Royal Prince Alfred Hospital, 50 Missenden Rd, Camperdown NSW 2050
Country 151659 0
Australia
Phone 151659 0
+61 295156111
Fax 151659 0
Email 151659 0
Contact person for scientific queries
Name 151660 0
Harry Baxter
Address 151660 0
Royal Prince Alfred Hospital, 50 Missenden Rd, Camperdown NSW 2050
Country 151660 0
Australia
Phone 151660 0
+61 295156111
Fax 151660 0
Email 151660 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocol  [email protected]


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.